Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY – Free Report) – Investment analysts at Erste Group Bank upped their FY2026 EPS estimates for Sandoz Group in a note issued to investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now expects that the company will earn $4.22 per share for the year, up from their prior forecast of $4.20. Erste Group Bank currently has a “Strong-Buy” rating on the stock. The consensus estimate for Sandoz Group’s current full-year earnings is $4.14 per share. Erste Group Bank also issued estimates for Sandoz Group’s FY2027 earnings at $4.56 EPS.
Sandoz Group Price Performance
OTCMKTS:SDZNY opened at $84.95 on Tuesday. Sandoz Group has a twelve month low of $60.35 and a twelve month high of $94.15. The company’s 50-day moving average price is $85.91 and its 200-day moving average price is $83.99.
Sandoz Group Company Profile
Sandoz Group AG is a Switzerland-based pharmaceutical company focused on developing, manufacturing and marketing generic and biosimilar medicines. Its portfolio is designed to expand access to established treatments by offering alternatives to branded products after patent or regulatory exclusivity periods end.
The company supplies medicines across a range of therapeutic areas, including anti-infectives, ophthalmology, respiratory care, central nervous system treatments, dermatology, transplantation and immunology.
Further Reading
- Five stocks we like better than Sandoz Group
- The Pentagon’s $350 Million Quantum Push: Why IonQ Could Benefit More Than D-Wave
- Delta’s Guidance Cut Could Spell Trouble for the Airline Industry
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.
